Compare Piramal Enterprises with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs VENUS REMEDIES - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES VENUS REMEDIES PIRAMAL ENTERPRISES/
VENUS REMEDIES
 
P/E (TTM) x -47.2 -9.9 - View Chart
P/BV x 1.6 0.7 240.0% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 PIRAMAL ENTERPRISES   VENUS REMEDIES
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
VENUS REMEDIES
Mar-18
PIRAMAL ENTERPRISES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs3,303126 2,623.2%   
Low Rs1,79761 2,940.8%   
Sales per share (Unadj.) Rs716.5301.8 237.4%  
Earnings per share (Unadj.) Rs79.7-24.9 -320.5%  
Cash flow per share (Unadj.) Rs107.92.5 4,240.5%  
Dividends per share (Unadj.) Rs28.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs1,477.5293.3 503.8%  
Shares outstanding (eoy) m184.4512.34 1,494.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.60.3 1,148.6%   
Avg P/E ratio x32.0-3.8 -850.9%  
P/CF ratio (eoy) x23.636.7 64.3%  
Price / Book Value ratio x1.70.3 541.3%  
Dividend payout %35.10-   
Avg Mkt Cap Rs m470,2921,154 40,760.6%   
No. of employees `0007.80.9 845.4%   
Total wages/salary Rs m22,504393 5,724.6%   
Avg. sales/employee Rs Th16,899.44,026.1 419.8%   
Avg. wages/employee Rs Th2,877.7425.0 677.1%   
Avg. net profit/employee Rs Th1,879.9-331.8 -566.6%   
INCOME DATA
Net Sales Rs m132,1533,724 3,548.6%  
Other income Rs m3,12823 13,902.2%   
Total revenues Rs m135,2813,747 3,610.8%   
Gross profit Rs m66,290395 16,790.7%  
Depreciation Rs m5,202338 1,537.5%   
Interest Rs m44,097354 12,446.3%   
Profit before tax Rs m20,119-275 -7,307.9%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,61132 27,250.9%   
Profit after tax Rs m14,701-307 -4,790.2%  
Gross profit margin %50.210.6 473.2%  
Effective tax rate %42.8-11.5 -372.9%   
Net profit margin %11.1-8.2 -135.0%  
BALANCE SHEET DATA
Current assets Rs m122,7422,638 4,653.4%   
Current liabilities Rs m310,8102,305 13,486.2%   
Net working cap to sales %-142.38.9 -1,591.4%  
Current ratio x0.41.1 34.5%  
Inventory Days Days23135 17.0%  
Debtors Days Days3946 83.8%  
Net fixed assets Rs m116,9044,871 2,400.1%   
Share capital Rs m369123 298.9%   
"Free" reserves Rs m272,1613,496 7,785.7%   
Net worth Rs m272,5303,619 7,530.3%   
Long term debt Rs m270,1961,374 19,659.2%   
Total assets Rs m856,2617,509 11,403.9%  
Interest coverage x1.50.2 653.1%   
Debt to equity ratio x1.00.4 261.1%  
Sales to assets ratio x0.20.5 31.1%   
Return on assets %6.90.6 1,087.8%  
Return on equity %5.4-8.5 -63.6%  
Return on capital %12.41.6 785.1%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m15,2000-   
Fx outflow Rs m4,889517 946.5%   
Net fx Rs m10,312-517 -1,996.4%   
CASH FLOW
From Operations Rs m-115,975514 -22,545.6%  
From Investments Rs m-8,265-123 6,714.1%  
From Financial Activity Rs m107,525-387 -27,777.0%  
Net Cashflow Rs m-16,6504 -396,433.3%  

Share Holding

Indian Promoters % 52.9 32.9 161.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 0.2 2,222.2%  
FIIs % 26.6 0.6 4,586.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 66.4 24.8%  
Shareholders   93,274 20,121 463.6%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Wipro's Biggest Acquisition, Vodafone Idea Fundraising Plan, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed huge selling during closing hours on Friday and ended lower.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Mar 5, 2021 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - GSK PHARMA COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS